DMAC
DiaMedica Therapeutics Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
6.52
■ 0.00 (0.00%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
6.58
Prev close
6.52
Day high
6.73
Day low
6.50
Volume
76.26K
Market cap
$351.60M
P/E (TTM)
—
52W range
5.14 – 10.42
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
15.01M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 10, 26 | PAULS DIETRICH JOHN Chief Executive Officer |
STOCK | 60.20K | $0 | Direct |
| Jan 2, 26 | PARSONS JAMES T CPA Director |
STOCK | 10.10K | $85.00K | Direct |
| Jan 2, 26 | GIUFFRE RANDALL MICHAEL M.D. Director |
STOCK | 6.17K | $51.99K | Direct |
| Jan 2, 26 | SEMBA CHARLES PAULING Director |
STOCK | 3.35K | $28.25K | Direct |
| Nov 25, 25 | STAHLBERG JAN Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.06M | $7.63M | Indirect |
| Nov 21, 25 | PARSONS JAMES T CPA Director |
CONVERSION | 12.00K | $26.40K | Direct |
| Aug 27, 25 | STAHLBERG JAN Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.00M | $5.96M | Indirect |
| Jul 23, 25 | JACINTO RICHARD II Beneficial Owner of more than 10% of a Class of Security |
BUY | 400.00K | $2.06M | Indirect |
| Jul 23, 25 | VON KOCH NILS THOMAS Beneficial Owner of more than 10% of a Class of Security |
BUY | 2.86M | $14.71M | Indirect |
| Jul 23, 25 | STAHLBERG JAN Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.54M | $7.95M | Indirect |
| Apr 7, 25 | PILNIK RICHARD D Director |
CONVERSION | 24.00K | $50.64K | Direct |
| Feb 13, 25 | GIUFFRE RANDALL MICHAEL M.D. Director |
CONVERSION | 17.00K | $43.57K | Direct |
| Jan 2, 25 | KUNTZ RICHARD P Director |
STOCK | 9.93K | $53.00K | Direct |
| Jan 2, 25 | PILNIK RICHARD D Director |
STOCK | 10.39K | $55.50K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
GIUFFRE RANDALL MICHAEL M.D. |
Director | 445.23K | Stock Award(Grant) |
JACINTO RICHARD II |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
KUNTZ RICHARD P |
Director | 24.21K | Stock Award(Grant) |
PARSONS JAMES T CPA |
Director | 97.95K | Stock Award(Grant) |
PAULS DIETRICH JOHN |
Chief Executive Officer | 128.79K | Stock Award(Grant) |
PILNIK RICHARD D |
Director | 313.00K | Conversion of Exercise of derivative security |
SEMBA CHARLES PAULING |
Director | 47.96K | Stock Award(Grant) |
STAHLBERG JAN |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
VON KOCH NILS THOMAS |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
0.00
Positioning, not flow
Max pain
7.50
+15.0% from spot
ATM implied vol
107.0%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
7.50
31 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-2.40%
-1.0%
1M
-4.40%
-8.1%
3M
+13.00%
+9.9%
6M
-22.57%
-33.6%
YTD
-18.09%
-30.4%
1Y
+8.67%
-11.3%
3Y
+111.69%
+37.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$351.60M
Enterprise value$308.28M
Revenue (TTM)—
Gross profit—
EBITDA$-39.17M
Net income$-37.54M
EPS (TTM)$-0.72
Free cash flow$-17.65M
Total cash$43.50M
Total debt$185.00K
Book value / share$0.71
Shares outstanding53.93M
Float25.30M
Short % of float14.38%
Dividend yield—
Beta (5Y)0.97
Short interest
Shares short
5.20M
Prior 5.21M
Change vs prior
-0.1%
Shorts covering
% of float
14.38%
Elevated
% of shares out
9.65%
Against total outstanding
Days to cover
23.7
Crowded exit
Float
25.30M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Valuation & profitability ratios
Trailing P/E—
Forward P/E-8.07
PEG ratio—
Price / sales—
Price / book9.17
EV / revenue—
EV / EBITDA-7.87
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-114.61%
Return on assets-64.12%
Debt / equity0.48
Current ratio6.72
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $24.61M | $19.06M | $13.11M | $7.84M | +29.2% |
| Selling, general & admin | $9.78M | $7.62M | $8.16M | $6.16M | +28.3% |
| Total operating expense | $34.40M | $26.68M | $21.27M | $14.00M | +28.9% |
| Operating income | -$34.40M | -$26.68M | -$21.27M | -$14.00M | -28.9% |
| Pre-tax income | -$32.74M | -$24.41M | -$19.34M | -$13.65M | -34.1% |
| Tax provision | $28.00K | $30.00K | $43.00K | $28.00K | -6.7% |
| Net income | -$32.77M | -$24.44M | -$19.38M | -$13.68M | -34.0% |
| Net income to common | -$32.77M | -$24.44M | -$19.38M | -$13.68M | -34.0% |
| Basic EPS | -0.70 | -0.60 | -0.60 | -0.52 | -16.7% |
| Diluted EPS | -0.70 | -0.60 | -0.60 | -0.52 | -16.7% |
| EBIT | -$34.40M | -$26.68M | -$21.27M | -$14.00M | -28.9% |
| EBITDA | -$34.35M | -$26.64M | -$21.24M | -$13.98M | -28.9% |
| Basic shares | 46.98M | 40.40M | 32.57M | 26.44M | +16.3% |
| Diluted shares | 46.98M | 40.40M | 32.57M | 26.44M | +16.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $15.65M | $3.02M | $4.54M | $4.73M | +417.3% |
| Cash & short-term investments | $59.89M | $44.15M | $52.90M | $33.50M | +35.7% |
| Accounts receivable | $8.00K | $1.00K | $71.00K | $2.00K | +700.0% |
| Total current assets | $60.63M | $44.61M | $53.67M | $33.84M | +35.9% |
| Property, plant & equipment | $342.00K | $427.00K | $485.00K | $560.00K | -19.9% |
| Total assets | $61.37M | $46.34M | $54.16M | $34.40M | +32.4% |
| Total current liabilities | $5.13M | $5.39M | $2.79M | $2.17M | -4.8% |
| Total debt | $240.00K | $340.00K | $400.00K | $469.00K | -29.4% |
| Total liabilities | $5.26M | $5.63M | $3.10M | $2.57M | -6.5% |
| Retained earnings | -$172.77M | -$140.00M | -$115.56M | -$96.18M | -23.4% |
| Shareholder equity | $56.11M | $40.72M | $51.06M | $31.83M | +37.8% |
| Working capital | $55.50M | $39.22M | $50.89M | $31.67M | +41.5% |
| Net tangible assets | $56.11M | $40.72M | $51.06M | $31.83M | +37.8% |
| Shares issued | 53.74M | 42.82M | 37.96M | 26.44M | +25.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$32.77M | -$24.44M | -$19.38M | -$13.68M | -34.0% |
| Depreciation & amortisation | $43.00K | $39.00K | $30.00K | $25.00K | +10.3% |
| Stock-based compensation | $3.85M | $2.08M | $1.68M | $1.50M | +84.5% |
| Change in working capital | $675.00K | $1.51M | $93.00K | $585.00K | -55.4% |
| Operating cash flow | -$29.06M | -$22.08M | -$18.73M | -$11.51M | -31.6% |
| Capital expenditure | -$40.00K | -$25.00K | -$24.00K | -$81.00K | -60.0% |
| Investing cash flow | -$2.19M | $8.56M | -$18.30M | $11.54M | -125.6% |
| Financing cash flow | $43.88M | $11.99M | $36.84M | -$6.00K | +265.8% |
| Free cash flow | -$29.10M | -$22.10M | -$18.75M | -$11.59M | -31.7% |
| End cash position | $15.65M | $3.02M | $4.54M | $4.73M | +417.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $7.99M | $6.70M | $6.44M | $5.82M | $5.66M | +19.2% |
| Selling, general & admin | $2.50M | $2.51M | $2.60M | $2.19M | $2.49M | -0.8% |
| Total operating expense | $10.48M | $9.21M | $9.03M | $8.01M | $8.14M | +13.8% |
| Operating income | -$10.48M | -$9.21M | -$9.03M | -$8.01M | -$8.14M | -13.8% |
| Pre-tax income | -$10.04M | -$8.73M | -$8.61M | -$7.69M | -$7.70M | -14.9% |
| Tax provision | $7.00K | $10.00K | $6.00K | $6.00K | $6.00K | -30.0% |
| Net income | -$10.04M | -$8.74M | -$8.62M | -$7.70M | -$7.71M | -14.9% |
| Net income to common | -$10.04M | -$8.74M | -$8.62M | -$7.70M | -$7.71M | -14.9% |
| Basic EPS | -0.19 | — | -0.17 | -0.18 | -0.18 | — |
| Diluted EPS | -0.19 | — | -0.17 | -0.18 | -0.18 | — |
| EBIT | -$10.48M | -$9.21M | -$9.03M | -$8.01M | -$8.14M | -13.8% |
| EBITDA | -$10.47M | -$9.20M | -$9.02M | -$8.00M | -$8.13M | -13.8% |
| Basic shares | 53.79M | — | 49.63M | 42.96M | 42.84M | — |
| Diluted shares | 53.79M | — | 49.63M | 42.96M | 42.84M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.87M | $15.65M | $3.33M | $4.11M | $2.59M | -68.9% |
| Cash & short-term investments | $51.33M | $59.89M | $55.32M | $30.04M | $36.32M | -14.3% |
| Accounts receivable | $16.00K | $8.00K | $32.00K | $19.00K | $24.00K | +100.0% |
| Total current assets | $52.36M | $60.63M | $56.22M | $31.08M | $37.42M | -13.6% |
| Property, plant & equipment | $317.00K | $342.00K | $368.00K | $391.00K | $408.00K | -7.3% |
| Total assets | $53.08M | $61.37M | $57.05M | $31.47M | $38.83M | -13.5% |
| Total current liabilities | $5.75M | $5.13M | $5.27M | $4.12M | $4.67M | +12.0% |
| Total debt | $212.00K | $240.00K | $266.00K | $292.00K | $316.00K | -11.7% |
| Total liabilities | $5.84M | $5.26M | $5.42M | $4.30M | $4.88M | +11.1% |
| Retained earnings | -$182.81M | -$172.77M | -$164.03M | -$155.41M | -$147.71M | -5.8% |
| Shareholder equity | $47.23M | $56.11M | $51.62M | $27.17M | $33.95M | -15.8% |
| Working capital | $46.62M | $55.50M | $50.95M | $26.96M | $32.76M | -16.0% |
| Net tangible assets | $47.23M | $56.11M | $51.62M | $27.17M | $33.95M | -15.8% |
| Shares issued | 53.88M | 53.74M | 52.08M | 43.07M | 42.86M | +0.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$10.04M | -$8.74M | -$8.62M | -$7.70M | -$7.71M | -14.9% |
| Depreciation & amortisation | $11.00K | $11.00K | $18.00K | $3.00K | $11.00K | 0.0% |
| Stock-based compensation | $822.00K | $1.19M | $1.02M | $771.00K | $867.00K | -31.0% |
| Change in working capital | $295.00K | $3.00K | $1.26M | -$513.00K | -$79.00K | +9,733.3% |
| Operating cash flow | -$9.08M | -$7.76M | -$6.55M | -$7.60M | -$7.15M | -17.0% |
| Capital expenditure | -$8.00K | -$6.00K | -$16.00K | -$6.00K | -$12.00K | -33.3% |
| Investing cash flow | -$2.11M | $8.00M | -$25.77M | $8.96M | $6.62M | -126.4% |
| Financing cash flow | $417.00K | $12.09M | $31.53M | $161.00K | $91.00K | -96.6% |
| Free cash flow | -$9.09M | -$7.77M | -$6.57M | -$7.60M | -$7.16M | -17.0% |
| End cash position | $4.87M | $15.65M | $3.33M | $4.11M | $2.59M | -68.9% |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.20 | -0.19 | +5.0% |
| Dec 2025 | -0.18 | -0.17 | +5.6% |
| Sep 2025 | -0.16 | -0.17 | -6.3% |
| Jun 2025 | -0.19 | -0.18 | +5.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.20 | 4 | $0 | 0.0% |
| Next quarter | -0.21 | 4 | $0 | 0.0% |
| Current year | -0.81 | 4 | $0 | 0.0% |
| Next year | -0.81 | 5 | $0 | 0.0% |
Analyst targets & ownership
Mean target$15.50
High target$25.00
Low target$11.00
Implied upside137.73%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders27.83%
Held by institutions40.91%
Institutions holding134
Price targets, consensus spread, insider and institutional ownership.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 14, 25 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Aug 15, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 18, 25 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Jul 18, 25 | Lake Street | MAINTAINED | Buy | Buy |
| Jul 18, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 29, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 15, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 10, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 7, 24 | HC Wainwright & Co. | INITIATED | — | Buy |
| Aug 16, 24 | Oppenheimer | MAINTAINED | Outperform | Outperform |
Moving averages & technicals
SMA 10
6.69
-2.50% from price
SMA 20
6.63
-1.71% from price
SMA 50
6.76
-3.59% from price
SMA 100
6.46
+0.87% from price
SMA 200
7.19
-9.26% from price
EMA 12
6.66
-2.11% from price
EMA 26
6.72
-2.91% from price
EMA 50
6.70
-2.67% from price
RSI (14)
44.1
Neutral
MACD (12,26,9)
-0.05
Hist -0.01
ATR (14)
0.31
4.69% of price
Realised vol 30D
39.5%
Annualised
Bollinger upper
6.93
20, 2σ
Bollinger lower
6.34
20, 2σ
50 / 200 cross
Death
6.76 vs 7.19
Trend bias
Below 200
-9.26%
Risk profile
Beta vs SPY
1.56
More volatile than market
Correlation to SPY
0.34
Loosely linked
Realised vol 30D
39.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-43.2%
Peak to trough
Max drawdown 5Y
-75.7%
Peak to trough
ATR 14
0.31
4.69% of price
Beta (reported)
0.97
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateNov 15, 2018
Last split1:20
Split dateNov 15, 2018
SEC filings
Offering Registrations
S-8 · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-05-21
Periodic Financial Reports
10-Q · 2026-05-06
Proxy Statements
DEFA14A · 2026-04-01
Corporate Changes & Voting Matters
8-K · 2026-03-31
Periodic Financial Reports
10-K · 2026-03-30
Corporate Changes & Voting Matters
8-K · 2026-01-05
Headlines
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript
Motley Fool · 5d ago
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
Zacks · 9d ago
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...
GuruFocus.com · 11d ago
DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary
Moby · 11d ago
DiaMedica Therapeutics Q2 Earnings Call Highlights
MarketBeat · 11d ago
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Business Wire · 12d ago
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
Business Wire · 18d ago
DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential
Insider Monkey · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.